• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磷酸二酯酶同工酶家族PDE III和PDE IV的选择性药理抑制剂之间的协同相互作用,以减弱大鼠血管平滑肌细胞的增殖。

Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.

作者信息

Pan X, Arauz E, Krzanowski J J, Fitzpatrick D F, Polson J B

机构信息

Department of Pharmacology and Therapeutics, College of Medicine, University of South Florida, Tampa 33612-4799.

出版信息

Biochem Pharmacol. 1994 Aug 17;48(4):827-35. doi: 10.1016/0006-2952(94)90062-0.

DOI:10.1016/0006-2952(94)90062-0
PMID:7521642
Abstract

The interaction between selective inhibitors of 3',5'-cyclic-nucleotide phosphodiesterase (PDE) III (cyclic GMP inhibited phosphodiesterase) and selective inhibitors of PDE IV (Ro 20-1724 inhibited phosphodiesterase) to attenuate fetal bovine serum-stimulated incorporation of [3H]thymidine into DNA and cell proliferation was studied in a line (A10) of vascular smooth muscle cells (VSMC). The nonselective PDE inhibitors 3-isobutyl-1-methylxanthine (IBMX) and papaverine attenuated DNA synthesis with EC50 values (16 and 18 microM, respectively) in the same range as their published IC50 values (2-50 and 2-25 microM, respectively) as PDE inhibitors. The selective PDE III inhibitors CI-930 and cilostamide used alone attenuated DNA synthesis with EC50 values (> 300 and 5.3 microM, respectively) that were much higher than published IC50 values (0.15-0.46 and 0.005-0.064 microM, respectively) for inhibition of PDE III. In the presence of the PDE IV inhibitor rolipram (10 microM), their EC50 values were shifted (0.66 and 0.16 microM, respectively) much closer to their respective IC50 values. When the selective PDE IV inhibitors rolipram and Ro 20-1724 were used alone, they attenuated DNA synthesis with EC50 values (111 and > 100 microM, respectively) much higher than their IC50 values (0.6-2.6 and 2-13 microM, respectively) as inhibitors of PDE IV, but 10 microM CI-930 (PDE III inhibitor) shifted their EC50 values (0.56 and 1.5 microM, respectively) much closer to their IC50 values. In experiments that assessed VSMC proliferation using the MTT [3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide] method, IBMX and papaverine attenuated proliferation with EC50 values (27 and 58 microM, respectively) close to their IC50 values. CI-930 and cilostamide used alone did not cause 50% attenuation of proliferation at the highest concentrations tested (100 and 10 microM, respectively). In the presence of 5 microM rolipram, however, their effects were enhanced greatly with EC50 values (0.86 and 0.23 microM, respectively) that were close to their IC50 values as PDE III inhibitors. Similarly, rolipram and Ro 20-1724 attenuated VSMC proliferation with EC50 values close to their IC50 values in the presence (2.1 and 4.6 microM, respectively) but not in the absence (> 100 and > 10 microM, respectively) of 2 microM CI-930. The interactions between PDE III inhibitors and PDE IV inhibitors to attenuate DNA synthesis and VSMC proliferation were synergistic as determined by the combination index. The data demonstrate that the synergistic interactions that attenuate incorporation of [3H]thymidine into DNA are accompanied by synergistic attenuations of VSMC division.(ABSTRACT TRUNCATED AT 400 WORDS)

摘要

在血管平滑肌细胞(VSMC)系(A10)中,研究了3',5'-环核苷酸磷酸二酯酶(PDE)III(环鸟苷酸抑制性磷酸二酯酶)的选择性抑制剂与PDE IV(Ro 20 - 1724抑制性磷酸二酯酶)的选择性抑制剂之间的相互作用,以减弱胎牛血清刺激的[3H]胸腺嘧啶核苷掺入DNA及细胞增殖。非选择性PDE抑制剂3 - 异丁基 - 1 - 甲基黄嘌呤(IBMX)和罂粟碱减弱DNA合成,其半数有效浓度(EC50)值(分别为16和18微摩尔)与它们作为PDE抑制剂已公布的半数抑制浓度(IC50)值(分别为2 - 50和2 - 25微摩尔)在同一范围内。单独使用的选择性PDE III抑制剂CI - 930和西洛他唑减弱DNA合成,其EC50值(分别> 300和5.3微摩尔)远高于已公布的抑制PDE III的IC50值(分别为0.15 - 0.46和0.005 - 0.064微摩尔)。在PDE IV抑制剂咯利普兰(10微摩尔)存在时,它们的EC50值发生偏移(分别为0.66和0.16微摩尔),更接近各自的IC50值。当单独使用选择性PDE IV抑制剂咯利普兰和Ro 20 - 1724时,它们减弱DNA合成,其EC50值(分别为111和> 100微摩尔)远高于它们作为PDE IV抑制剂的IC50值(分别为0.6 - 2.6和2 - 13微摩尔),但10微摩尔CI - 930(PDE III抑制剂)使它们的EC50值(分别为0.56和1.5微摩尔)更接近各自的IC50值。在使用MTT [3 - (4,5 - 二甲基噻唑 - 2 - 基) - 2,5 - 二苯基四氮唑溴盐]法评估VSMC增殖的实验中,IBMX和罂粟碱减弱增殖,其EC50值(分别为27和58微摩尔)接近它们的IC50值。单独使用CI - 930和西洛他唑在测试的最高浓度(分别为100和10微摩尔)下未引起50%的增殖减弱。然而,在5微摩尔咯利普兰存在时,它们的作用显著增强,EC50值(分别为0.86和0.23微摩尔)接近它们作为PDE III抑制剂的IC50值。同样,咯利普兰和Ro 20 - 1724在2微摩尔CI - 930存在时(分别为2.1和4.6微摩尔)减弱VSMC增殖,其EC50值接近它们的IC50值,而在不存在CI - 930时(分别> 100和> 10微摩尔)则不然。根据合并指数测定,PDE III抑制剂与PDE IV抑制剂之间减弱DNA合成和VSMC增殖的相互作用是协同的。数据表明,减弱[3H]胸腺嘧啶核苷掺入DNA的协同相互作用伴随着VSMC分裂的协同减弱。(摘要截断于400字)

相似文献

1
Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells.磷酸二酯酶同工酶家族PDE III和PDE IV的选择性药理抑制剂之间的协同相互作用,以减弱大鼠血管平滑肌细胞的增殖。
Biochem Pharmacol. 1994 Aug 17;48(4):827-35. doi: 10.1016/0006-2952(94)90062-0.
2
Inhibition of pig aortic smooth muscle cell DNA synthesis by selective type III and type IV cyclic AMP phosphodiesterase inhibitors.选择性III型和IV型环磷酸腺苷磷酸二酯酶抑制剂对猪主动脉平滑肌细胞DNA合成的抑制作用
Biochem Pharmacol. 1992 Sep 1;44(5):857-66. doi: 10.1016/0006-2952(92)90116-z.
3
Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors.
Am J Physiol. 1994 May;266(5 Pt 1):L536-43. doi: 10.1152/ajplung.1994.266.5.L536.
4
Differential effects of non-selective and selective phosphodiesterase inhibitors on human eosinophil functions.非选择性和选择性磷酸二酯酶抑制剂对人嗜酸性粒细胞功能的不同影响。
Br J Pharmacol. 1995 Feb;114(4):821-31. doi: 10.1111/j.1476-5381.1995.tb13278.x.
5
Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity.类型选择性磷酸二酯酶抑制剂对葡萄糖诱导的胰岛素分泌及胰岛磷酸二酯酶活性的影响。
Br J Pharmacol. 1995 Aug;115(8):1486-92. doi: 10.1111/j.1476-5381.1995.tb16641.x.
6
Prevention by phosphodiesterase inhibitors of antigen-induced contraction of guinea-pig colonic smooth muscle.磷酸二酯酶抑制剂对豚鼠结肠平滑肌抗原诱导收缩的预防作用。
Br J Pharmacol. 1994 Jan;111(1):259-63. doi: 10.1111/j.1476-5381.1994.tb14053.x.
7
Comparison of phosphodiesterase III, IV and dual III/IV inhibitors on bronchospasm and pulmonary eosinophil influx in guinea pigs.磷酸二酯酶III、IV及双重III/IV抑制剂对豚鼠支气管痉挛和肺嗜酸性粒细胞浸润的比较。
J Pharmacol Exp Ther. 1994 Jul;270(1):250-9.
8
Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol.IV型磷酸二酯酶抑制剂对人嗜酸性粒细胞呼吸爆发和环磷酸腺苷水解的抑制作用:与β肾上腺素能受体激动剂沙丁胺醇的相互作用
J Pharmacol Exp Ther. 1994 Dec;271(3):1167-74.
9
Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization.调节人类气道固有张力的磷酸二酯酶同工酶:鉴定与特性分析
Am J Physiol. 1993 May;264(5 Pt 1):L458-64. doi: 10.1152/ajplung.1993.264.5.L458.
10
Role of phosphodiesterases III and IV in the modulation of vascular cyclic AMP content by the NO/cyclic GMP pathway.磷酸二酯酶III和IV在通过一氧化氮/环鸟苷酸途径调节血管环磷酸腺苷含量中的作用。
Br J Pharmacol. 1994 Oct;113(2):445-50. doi: 10.1111/j.1476-5381.1994.tb17009.x.

引用本文的文献

1
Ending Restenosis: Inhibition of Vascular Smooth Muscle Cell Proliferation by cAMP.抑制血管平滑肌细胞增殖以防止再狭窄:cAMP 的作用。
Cells. 2019 Nov 16;8(11):1447. doi: 10.3390/cells8111447.
2
Risk of Heart Failure Hospitalization Associated With Cilostazol in Diabetes: A Nationwide Case-Crossover Study.西洛他唑与糖尿病患者心力衰竭住院风险:一项全国性病例交叉研究。
Front Pharmacol. 2019 Jan 7;9:1467. doi: 10.3389/fphar.2018.01467. eCollection 2018.
3
Open-Label Phase I Clinical Study to Assess the Safety and Efficacy of Cilostazol in Patients Undergoing Internal Carotid Artery Stent Placement.
评估西洛他唑在接受颈内动脉支架置入术患者中的安全性和有效性的开放标签I期临床研究。
Interv Neurol. 2017 Mar;6(1-2):42-48. doi: 10.1159/000452308. Epub 2016 Dec 8.
4
No Association Between Single-Nucleotide Polymorphism 56 (SNP56) in Phosphodiesterase 4D (PDE4D) Gene and Susceptibility to Ischemic Stroke: A Meta-Analysis of 15 Studies.磷酸二酯酶 4D(PDE4D)基因单核苷酸多态性 56(SNP56)与缺血性脑卒中易感性之间无关联:15 项研究的荟萃分析。
Med Sci Monit. 2016 Oct 19;22:3820-3827. doi: 10.12659/MSM.896904.
5
Regulation of soluble guanylyl cyclase redox state by hydrogen sulfide.硫化氢对可溶性鸟苷酸环化酶氧化还原状态的调节
Pharmacol Res. 2016 Sep;111:556-562. doi: 10.1016/j.phrs.2016.06.029. Epub 2016 Jul 1.
6
Association between phosphodiesterase 4D (PDE4D) SNP 87 and ischemic stroke: a meta-analysis.磷酸二酯酶4D(PDE4D)基因单核苷酸多态性87与缺血性中风的关联:一项荟萃分析。
Int J Clin Exp Med. 2015 Feb 15;8(2):1715-25. eCollection 2015.
7
Clinical efficacy and safety of cilostazol: a critical review of the literature.西洛他唑的临床疗效和安全性:文献综述。
Drugs. 2015 Mar;75(4):377-95. doi: 10.1007/s40265-015-0364-3.
8
Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy.严重肢体缺血中脂蛋白相关磷脂酶A2、半乳糖凝集素-3、RhoA/ROCK及内皮祖细胞的水平和数值:西洛他唑与氯吡格雷联合治疗的药物治疗作用
J Transl Med. 2014 Apr 17;12:101. doi: 10.1186/1479-5876-12-101.
9
Combination of cilostazol and clopidogrel attenuates rat critical limb ischemia.西洛他唑联合氯吡格雷减轻大鼠肢体缺血危象。
J Transl Med. 2012 Aug 16;10:164. doi: 10.1186/1479-5876-10-164.
10
The effectiveness and safety of triple-antiplatelet treatment based on cilostazol for patients receiving percutaneous coronary intervention: a meta-analysis.基于西洛他唑的三联抗血小板治疗对接受经皮冠状动脉介入治疗患者的疗效和安全性:一项荟萃分析。
Clin Cardiol. 2012 Oct;35(10):598-604. doi: 10.1002/clc.22001. Epub 2012 May 14.